Sentences with phrase «use of growth factors»

PNNL recently filed a patent on the use of this growth factor - hydrogel complex for the stimulation of bone healing.

Not exact matches

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

The study ranked urban centers — excluding the larger metro areas — using three factors: local business environment (length of the average workweek, revenue growth, industry variety), access to resources (financing and the amount of venture capital investment made per capita), and costs (office space affordability, labor costs, corporate taxes, and cost of living).

The portfolio management team uses a variety of investment strategies to search for companies suitable for investment in the fund, including factors such as growth in earnings, return on equity, and revenue.

Important factors that may affect the Company's business and operations and that may cause actual results to differ materially from those in the forward - looking statements include, but are not limited to, increased competition; the Company's ability to maintain, extend and expand its reputation and brand image; the Company's ability to differentiate its products from other brands; the consolidation of retail customers; the Company's ability to predict, identify and interpret changes in consumer preferences and demand; the Company's ability to drive revenue growth in its key product categories, increase its market share, or add products; an impairment of the carrying value of goodwill or other indefinite - lived intangible assets; volatility in commodity, energy and other input costs; changes in the Company's management team or other key personnel; the Company's inability to realize the anticipated benefits from the Company's cost savings initiatives; changes in relationships with significant customers and suppliers; execution of the Company's international expansion strategy; changes in laws and regulations; legal claims or other regulatory enforcement actions; product recalls or product liability claims; unanticipated business disruptions; failure to successfully integrate the Company; the Company's ability to complete or realize the benefits from potential and completed acquisitions, alliances, divestitures or joint ventures; economic and political conditions in the nations in which the Company operates; the volatility of capital markets; increased pension, labor and people - related expenses; volatility in the market value of all or a portion of the derivatives that the Company uses; exchange rate fluctuations; disruptions in information technology networks and systems; the Company's inability to protect intellectual property rights; impacts of natural events in the locations in which the Company or its customers, suppliers or regulators operate; the Company's indebtedness and ability to pay such indebtedness; the Company's dividend payments on its Series A Preferred Stock; tax law changes or interpretations; pricing actions; and other factors.

Critics of the Modi government have often used lack of job growth as one of the factors to criticise the...

The favorable growth rate that led to the funding is more likely a factor of selling the coin - sized TrackR medallions for key rings and other every - day carry items and use of the mobile app.

Important factors that may affect the Company's business and operations and that may cause actual results to differ materially from those in the forward - looking statements include, but are not limited to, operating in a highly competitive industry; changes in the retail landscape or the loss of key retail customers; the Company's ability to maintain, extend and expand its reputation and brand image; the impacts of the Company's international operations; the Company's ability to leverage its brand value; the Company's ability to predict, identify and interpret changes in consumer preferences and demand; the Company's ability to drive revenue growth in its key product categories, increase its market share, or add products; an impairment of the carrying value of goodwill or other indefinite - lived intangible assets; volatility in commodity, energy and other input costs; changes in the Company's management team or other key personnel; the Company's ability to realize the anticipated benefits from its cost savings initiatives; changes in relationships with significant customers and suppliers; the execution of the Company's international expansion strategy; tax law changes or interpretations; legal claims or other regulatory enforcement actions; product recalls or product liability claims; unanticipated business disruptions; the Company's ability to complete or realize the benefits from potential and completed acquisitions, alliances, divestitures or joint ventures; economic and political conditions in the United States and in various other nations in which we operate; the volatility of capital markets; increased pension, labor and people - related expenses; volatility in the market value of all or a portion of the derivatives we use; exchange rate fluctuations; risks associated with information technology and systems, including service interruptions, misappropriation of data or breaches of security; the Company's ability to protect intellectual property rights; impacts of natural events in the locations in which we or the Company's customers, suppliers or regulators operate; the Company's indebtedness and ability to pay such indebtedness; the Company's ownership structure; the impact of future sales of its common stock in the public markets; the Company's ability to continue to pay a regular dividend; changes in laws and regulations; restatements of the Company's consolidated financial statements; and other factors.

Important factors that may affect the Company's business and operations and that may cause actual results to differ materially from those in the forward - looking statements include, but are not limited to, increased competition; the Company's ability to maintain, extend and expand its reputation and brand image; the Company's ability to differentiate its products from other brands; the consolidation of retail customers; the Company's ability to predict, identify and interpret changes in consumer preferences and demand; the Company's ability to drive revenue growth in its key product categories, increase its market share or add products; an impairment of the carrying value of goodwill or other indefinite - lived intangible assets; volatility in commodity, energy and other input costs; changes in the Company's management team or other key personnel; the Company's inability to realize the anticipated benefits from the Company's cost savings initiatives; changes in relationships with significant customers and suppliers; execution of the Company's international expansion strategy; changes in laws and regulations; legal claims or other regulatory enforcement actions; product recalls or product liability claims; unanticipated business disruptions; failure to successfully integrate the business and operations of the Company in the expected time frame; the Company's ability to complete or realize the benefits from potential and completed acquisitions, alliances, divestitures or joint ventures; economic and political conditions in the nations in which the Company operates; the volatility of capital markets; increased pension, labor and people - related expenses; volatility in the market value of all or a portion of the derivatives that the Company uses; exchange rate fluctuations; risks associated with information technology and systems, including service interruptions, misappropriation of data or breaches of security; the Company's inability to protect intellectual property rights; impacts of natural events in the locations in which the Company or its customers, suppliers or regulators operate; the Company's indebtedness and ability to pay such indebtedness; tax law changes or interpretations; and other factors.

Some of this difference is driven by slightly different growth factors; for example, VONG looks at book - to - price ratios, medium - term growth forecasts and historical sales - per - share growth, while IWY only uses the latter two factors.

Though the ECB has acknowledged that one of the main factors underlying the eurozone's stagnation is a lack of credit growth, any potential use of QE seems unlikely to make much of an impact in this regard, even if an announcement of QE could drive yields down further, making it even less attractive for banks to hold government bonds.

Global demand for Bitcoins is influenced by such factors as the growth of retail merchants» and commercial businesses» acceptance of Bitcoins as payment, the security of online Bitcoin Exchanges and digital wallets that hold Bitcoins, the perception that the use of Bitcoins is safe and secure, and the lack of regulatory restrictions on their use.

Availing the research developed by Persistence Market Research on the global frozen foods market, industrialists and market strategists can deduce the key factors driving the market's growth and use the risk assessment information for directing the growth of their frozen foods businesses.

Your patients should not use ZO ® OSSENTIAL ® GROWTH FACTOR SERUM PLUS if they are allergic or sensitive to any of its ingredients.

Hybridoma supernatants were screened for anti-rGRF activity by use of a pituitary culture assay system that can detect growth hormone - releasing factor in the femtomole range.

«To derive lineages, people use soluble growth factors to get the cells to differentiate,» explains Laura Kiessling, a UW - Madison professor of chemistry and biochemistry and stem cell expert.

But recent research has linked their long term use to various unwanted effects, including pneumonia, heart attack, and bone fracture, they point out, adding that PPIs are known to stimulate the production of gastrin, a powerful growth factor.

Researchers found that a combination of drugs — one targeting epidermal growth factor receptor (EGFR) and one targeting tumor necrosis factor (TNF)-- effectively blocks the cancer from using TNF as an escape route.

By using a range of tissue stains, they were able to assess levels of oestrogen receptor (ER), progesterone receptor (PR) and HER2 — human epidermal growth factor — in order to divide the samples into four subtypes.

Designed for use in spinal fusion surgery of the lower back, Infuse consists of a titanium cage that houses a collagen sponge soaked in bone morphogenetic protein (BMP), a growth factor that signals bone - forming cells to produce new tissue.

We don't need to use a cocktail of small molecules, growth factors or other supplements to create a population of bone cells from human pluripotent stem cells like induced pluripotent stem cells,» Varghese said.

«Scientifically, she worked on a project that not only revealed an important role for a specific growth factor (VEGF) in the physiology of an ocular structure called the ciliary body but she also demonstrated that there might be unexpected and undesired side effects from a widely used treatment for a variety of ocular diseases.

In addition, using methods for the analysis of regulatory networks developed by the Califano lab in the Center for Computational Biology and Bioinformatics, Department of Systems Biology, the researchers identified a number of transcription factors (gene regulators) that have the potential to mimic the environmental signals that trigger papillae to induce new hair growth.

Eventually, she says, it might be possible to use our increased understanding of RFX transcription factor to treat hearing loss, by either protecting hair cells from death or fostering their growth.

Previously, stem cells have been made to differentiate into lung cells using a cocktail of different growth factors, but Haute says using physical forces might be simpler.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Combined with a commercial serum containing skin growth factor, use of the beauty patch — which is based on electrical energy from sugar and air — led to a 90 % percent increase in collagen fibres, which help to keep the skin supple, after the two - week test.

«Using what has been learned from the Lewin paper,» it might be possible to tweak the receptor for nerve growth factor to limit this side effect, says Lorne Mendell, a neuroscientist at the State University of New York at Stony Brook.

Publishing in Science, an EPFL group has used bioengineering to significantly improve the efficacy of clinical growth factors in the context of soft tissue and bone repair, while maintaining low and safe doses.

These cells were encouraged to grow into cultured red blood cells using a cocktail of growth factors.

These biologic therapies use an antibody class called immunoglobulin - G (IgG) to bind to and prevent the activity of specific proteins or growth factors.

He is using growth factors to encourage severed nerves of the central nervous system to grow

Researchers are also targeting growth factors involved in new bone formation, with promising results in techniques using transplantation of genetically modified donor bone.

Strategies under investigation at this time include the use of drugs, growth factors, anti-growth factors, surgery, and radiation.

Several research groups are pursuing gene therapy approaches to regenerate skin, such as using genes to control expression of growth factors involved in skin healing.

Su - chun Zhang and his colleagues at the University of Wisconsin, Madison, and the University of Bonn, Germany, directed the development of embryonic stem cells stage by stage, using the same growth factors the body uses.

This new technology may contribute to medical cost reduction while maintaining the quality of medical treatment without using growth factors that are expensive and prone to deactivation.

«One of the major advantages, in a practical sense, is that we are using much less growth factor,» said McDevitt, who is also director of the Stem Cell Engineering Center at Georgia Tech.

In consideration of these issues, the research group developed porous films using pig - skin - derived gelatin chemically modified with hexanoyl group that is believed to provide superb tissue adhesiveness and excellent bonding to growth factors.

In addition to providing a platform for studying the processes that regulate platelet production and related diseases, the researchers hope the platelets produced can be used as a source of growth factors for wound healing in regenerative medicine, including healing of ulcers and burns, and stimulation of bone tissue regeneration in dentistry and maxillofacial plastic surgery.

Researchers are now reporting advances in these areas by using gelatin - based microparticles to deliver growth factors to specific areas of embryoid bodies, aggregates of differentiating stem cells.

When Ralph Arlinghaus, a molecular biologist at the University of Texas MD Anderson Cancer Center in Houston, learned that growth factor — starved healthy cells release a protein called 24p3 that causes them to die, he wondered if leukemia cells also use the molecule to kill off their competition.

«Using new microscopy techniques, we could show that the receptor of a well known growth factor, EGF, plays an important role in tight junction barrier formation in the epidermis.

The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost - effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study published online by JAMA Ophthalmology.

Perhaps the ultimate solution to keeping transplanted stem cells alive will be to use helpers that give off a cocktail of growth factors, he suggests, as well as pre-conditioning for low oxygen conditions and scaffolds.

Dr Smout said the discovery means it's possible the growth factor could be used to accelerate the healing of chronic wounds such as diabetic ulcers and to develop a vaccine against the worm - induced cancer.

This study opens up the possibility of using this growth factor to treat diseases like osteoporosis,» said Dr. Sean Morrison, who led the team that made the discovery.

Complementing this work are recent advances at Joslin identifying new islet growth in patients with long - standing type 1 diabetes, as well as identifying potential islet growth factors, which occur in situations of insulin resistance, that could be used to stimulate the growth of the patient's own beta cells.

Hepatocyte growth factor (HGF)(or scatter factor (SF) pathways - Met inhibitors could be used in combination with other treatment modalities such as; radiotherapy and / or immunotherapy in treatment of cutaneous melanoma.

The first relies on the biochemical properties of a drug, while the second uses the antigen / antibody connection.26 The use of biotynilated - epidermal growth factor (EGFR) has been used to enhance the accumulation of cisplatin.27 Other local factors in the respiratory system influencing the absorption are the local transporters and genes.